Under construction – not a live service
Sign in
Taking people in Saudi ArabiaNo phase

Following teens and adults with atopic dermatitis as they start or change systemic treatment

Follows adolescents and adults with atopic dermatitis starting or switching systemic treatments.

Key facts

Who runs it
Sanofi
Where
Jeddah and Riyadh, Saudi ArabiaSee the 3 sitesAlso in 8 other countries, 79 sites
Trial code
Registry title
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Status
Recruiting
People taking part
1,000 people, planned
Started
17 Nov 2025
Expected to end
30 Jan 2034
Type of study
Observational
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12 and older with atopic dermatitis who are about to start a systemic treatment. It follows them in everyday care for 5 years.

Age
12 years and older
Sex
All sexes
Disease stage
Confirmed atopic dermatitis (ICD-10 code L20), of any severity.
Earlier treatment
Must be prescribed and scheduled to start a systemic treatment for atopic dermatitis, such as biologics, oral JAK inhibitors, cyclosporine, azathioprine, methotrexate or mycophenolate mofetil.

Main reasons for not taking part

  • Taking part in an interventional trial with an investigational drug that changes patient care
  • Not understanding the study well enough (patient or parent/guardian)

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients aged more than or equal to (≥) 12 years at the time of consent
  • Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20
  • Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil)
  • Signed informed consent for registry participation by the patient or parent/legal representative and assent by the patient appropriate to the patient's age, including willingness to participate in long-term follow-up

Who cannot take part

  • Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care
  • Insufficient understanding of the study by the patient and/or parent/guardian; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Where in Saudi Arabia

Also in 8 other countries, 79 sites

  • Erfan and Bagedo Hospital-Site Number : 6820002Jeddah, Saudi ArabiaContact: Ahmed Ismail Ebraheem AbdellateefTaking people
  • Medical Fakeeh-Site Number : 6820003Jeddah, Saudi ArabiaContact: Ayman ElgendiTaking people
  • King Fahad Medical City-Site Number : 6820001Riyadh, Saudi ArabiaContact: Mohammed AlajlanTaking people

About the trial

What the trial wants to find out

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.

Read full original descriptionShow less

The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.

The group in the trial

  • Atopic Dermatitis

    This study plans to collect information on adolescent and adult patients with atopic dermatitis who initiate or switch any systemic treatment (eg, biologics, oral Janus kinase \[JAK\] inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) for AD according to the country-specific prescribing information. During the study, investigators will prescribe medical products for treatment of AD per standard of care (SoC) and per medical judgment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Atopic Dermatitis Disease Registry of Adult and Adolescent Patients Initiating or Switching Systemic Treatments
Plain-language title
Following teens and adults with atopic dermatitis as they start or change systemic treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
2 November 2026